Treatment with pioglitazone versus placebo

2 trials

Sponsors

Medical Research Council (UK), Takeda Europe R and D Centre (UK)

Conditions

Familial Combined Hyperlipidaemia Nutritional, Metabolic, Endocrine Hyperlipidaemia

Unknown Phase

A pilot study to investigate the effect of pioglitazone on muscle and liver triglyceride content and total body fat in patients with familial combined hyperlipidaemia: relation to parameters of lipid and carbohydrate metabolism

Active, not recruitingISRCTN34596899

Medical Research Council (UK)Familial Combined Hyperlipidaemia Nutritional, Metabolic, Endocrine Hyperlipidaemia

Start: 2002-12-18Target: 26Updated: 2015-01-13

A study to investigate the effect of pioglitazone on whole body and myocardial glucose uptake and myocardial blood flow/coronary vasodilator reserve in patients with familial combined hyperlipidaemia

Active, not recruitingISRCTN78563659

Takeda Europe R and D Centre (UK)Familial Combined Hyperlipidaemia Nutritional, Metabolic, Endocrine Hyperlipidaemia

Start: 2004-05-01Target: 26Updated: 2015-01-13

Related Papers

Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study.

2007-11-0528 citations